Login to Your Account

Neurochem Signs Potential $54M Deal With Centocor For Fibrillex

By Karen Pihl-Carey

Thursday, December 23, 2004
Just a few weeks after completing the treatment portion of a Phase II/III trial of Fibrillex, Neurochem Inc. partnered its AA amyloidosis drug with Centocor Inc. in a deal worth up to $54 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription